Ayala Pharmaceuticals (NASDAQ:ADXS) Receives New Coverage from Analysts at StockNews.com

Posted by Tyrone Williams on Oct 20th, 2024

StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Free Report) in a research report report published on Thursday. The firm issued a sell rating on the stock.

Ayala Pharmaceuticals Price Performance

Shares of ADXS opened at $0.03 on Thursday. The stock has a 50-day moving average of $0.03 and a 200-day moving average of $0.21. The company has a market cap of $1.15 million, a PE ratio of 0.00 and a beta of 1.72. Ayala Pharmaceuticals has a one year low of $0.00 and a one year high of $1.49.

About Ayala Pharmaceuticals

(Get Free Report)

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.